The Efficacy of an Innovative Method of Melanocytes-Keratinocytes Suspension for the Treatment of Stable Vitiligo (A Report of 20 Cases)

Document Type : Case Report

Authors

1 Professor, Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

2 Associate Professor, Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran AND Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

3 General Practitioner, Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

4 Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Vitiligo is the most common chronic depigmentation disorder caused by melanocyte loss in the basal epidermis. Drug therapy and surgical procedures are two main modalities for its treatment and one of the most effective surgical procedures is non-cultured epidermal cell transplantation suspension containing melanocytes and keratinocytes cells. This pilot study evaluates the effectiveness of an innovative method of melanocyte-keratinocyte cell suspension for treatment of patients with stable vitiligo.Methods: Twenty patients with stable vitiligo which where resistant to standard treatment participated in this study. Melanocyte- keratinocyte cell suspension (with Patent No. 81687 method) was transferred to the affected lesions. Repigmentation of the lesions was scored as excellent, good, fair or weak by comparing lesion photos before and 6 months after the treatment.Findings: Mean repigmentation score was excellent in 1(5%), good in 4(20%), fair in 11(55%) and weak in 4 (20%) of the patients 6 months after the intervention.Conclusion: The results of this study demonstrated that melanocyte-keratinocyte cell suspension can provide good results and repigmentation in more than 50% of cases.

Keywords

References

  1. Wagner RY, Luciani F, Cario-Andre M, Rubod A, Petit V, Benzekri L, et al. Altered E-cadherin levels and distribution in melanocytes precede clinical manifestations of vitiligo. J Invest Dermatol 2015; 135(7): 1810-9.
  2. Rathore B, Garg K, Misra A, Misra D, Mahdi F. Effect of anti-oxidant supplementation in vitiligo patients during narrow band UVB phototherapy. Int J Pharmacogn 2014; 1(11): 724-9.
  3. Li S, Yao W, Pan Q, Tang X, Zhao S, Wang W, et al. Association analysis revealed one susceptibility locus for vitiligo with immune-related diseases in the Chinese Han population. Immunogenetics 2015; 67(7): 347-54.
  4. Kasumagic-Halilovic E, Ovcina-kurtovic N, Helppikangas H. Anti-thyroglobulin antibody and vitiligo: A controlled study. Our Dermatol Online 2015; 6(2): 145-8.
  5. Lotti T, D'Erme AM. Vitiligo as a systemic disease. Clin Dermatol 2014; 32(3): 430-4.
  6. Faria AR, Tarle RG, Dellatorre G, Tavora Mira M, de Castro CCS. Vitiligo-part 2- classification, histopathology and treatment. An Bras Dermatol 2014; 89(5): 784-90.
  7. van Geel N, Goh B, Wallaeys E, de Keyser S, Lambert J. A review of non-cultured epidermal cellular grafting in vitiligo. J Cutan Aesthet Surg 2011; 4(1): 17-22.
  8. Wassef C, Lombardi A, Khokher S, Rao BK. Vitiligo surgical, laser, and alternative therapies: a review and case series. J Drugs Dermatol 2013; 12(6): 685-91.
  9. Verma R, Grewal RS, Chatterjee M, Pragasam V, Vasudevan B, Mitra D. A comparative study of efficacy of cultured versus non cultured melanocyte transfer in the management of stable vitiligo. Med J Armed Forces India 2014; 70(1): 26-31.
  10. Daniel BS, Wittal R. Vitiligo treatment update. Australas J Dermatol 2015; 56(2): 85-92.
  11. Zhang Y, Mooneyan-Ramchurn JS, Zuo N, Feng Y, Xiao S. Vitiligo nonsurgical treatment: a review of latest treatment researches. Dermatol Ther 2014; 27(5): 298-303.
  12. Sobhy N, Atia A, Elramly M. Some modifications in transplantation of autologus non-cultured melanocytes-keratinocytes suspension in treatment of segmental and focal vitiligo (Egyptian experience in Alexandria university). Our Dermatol Online 2013; 4(1): 5-10.
  13. Kumar R, Parsad D, Singh C, Yadav S. Four compartment method: a simplified and cost-effective method of noncultured epidermal cell suspension for the treatment of vitiligo. Br J Dermatol 2014; 170(3): 581-5.
  14. Olsson MJ, Juhlin L. Leucoderma treated by transplantation of a basal cell layer enriched suspension. Br J Dermatol 1998; 138(4): 644-8.
  15. Mulekar SV. Surgical management of vitiligo. Expert Review of Dermatology 2010; 5(2): 229-39.
  16. Ramos MG, Ramos DG, Gontijo G, Ramos CG, Rocha TN, Rocha RH. Non-cultured melanocyte/keratinocyte transplantation for the treatment of stable vitiligo on the face: report of two cases. An Bras Dermatol 2013; 88(5): 811-3.
  17. Holla A, Kumar R, Parsad D, Kanwar AJ. Modified procedure of noncultured epidermal suspension transplantation: changes are the core of vitiligo surgery. J Cutan Aesthet Surg 2011; 4(1): 44-5.
  18. van Geel N, Ongenae K, de Mil M, Naeyaert JM. Modified technique of autologous noncultured epidermal cell transplantation for repigmenting vitiligo: a pilot study. Dermatol Surg 2001; 27(10): 873-6.
  19. Goh BK, Chua XM, Chong KL, de Mil M, van Geel NA. Simplified cellular grafting for treatment of vitiligo and piebaldism: the "6-well plate" technique. Dermatol Surg 2010; 36(2): 203-7.
  20. Nilforoushzadeh MA, Jaffary F, Haftbaradaran E, Nasresfahani MH. The effect of melanocyte cell suspension in jokliks medium in the treatment of stable resistant vitiligo: report of 10 cases. J Isfahan Med Sch 2014; 32(314): 2210-6. [In Persian].
  21. Paul M. Autologous non-cultured basal cell-enriched epidermal cell suspension transplantation in vitiligo: Indian experience. J Cutan Aesthet Surg 2011; 4(1): 23-8.
  22. Huggins RH, Henderson MD, Mulekar SV, Ozog DM, Kerr HA, Jabobsen G, et al. Melanocyte-keratinocyte transplantation procedure in the treatment of vitiligo: the experience of an academic medical center in the United States. J Am Acad Dermatol 2012; 66(5): 785-93.
Journal of Isfahan Medical School
Volume 34, Issue 370 - Serial Number 370
January and February 2016
Pages 74-79

Files

History

  • Receive Date: 21 November 2015
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics